DURHAM, N.C., Sept. 21, 2010 (GLOBE NEWSWIRE) -- Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp (OTCBB:CURX), today commented on significant new research in the search for an effective treatment for those suffering from Alzheimer's disease. The research titled "The Alzheimer's Disease –Associated Amyloid B-Protein Is an Antimicrobial Peptide," was published by PLoS ONE, an international, on-line publication.
"We believe that this research carried out by Dr. Rudolph Tanzi of Harvard Medical School and his associates, represents a significant turning point in traditional thinking about beta amyloid as a factor in Alzheimer's disease. Pharmaceutical companies have spent billions of dollars pursuing a treatment for Alzheimer's by attempting to clear beta amyloid from the brain. Dr. Tanzi's research notes that beta amyloid is a part of the brain's innate immune system, and plays a role in protecting the brain from infection. Strategies that target beta amyloid elimination or clearance from the brain are clearly inappropriate," states Mr. Smith.
Curaxis for a decade has maintained that a strategy that focuses solely on beta amyloid clearance is an inappropriate goal. Curaxis' position has been borne out by multiple third party clinical trials, and the company's Alzheimer's disease candidate, Memryte, addresses the pathologies of Alzheimer's through multiple pathways.This multi-prong approach makes the company unique in the Alzheimer's space.
"As we ramp up our efforts to launch a Phase 2b trial of Memryte in women, we are excited about the opportunity to produce data as compelling as the data obtained in our earlier Phase 2a trial of those suffering from mild-to-moderate Alzheimer's. We believe Memryte could be the first disease modifying treatment for Alzheimer's disease," added Patrick Smith.
About Curaxis
Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. We believe our discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer's disease as well as many cancers. For more information, please visit .
Notice Regarding Forward Looking Statements
This press release includes certain "Forward-Looking Statements" within the meaning of section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding potential results and future plans and objectives of Curaxis Pharmaceutical Corporation are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the Securities and Exchange Commission. Other risk factors may include, but are not limited to, fluctuation in quarterly results, and increased competition in our operations, our ability to continue operations as scheduled, and our ability to protect the proprietary technology we use. Further, the company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the company's control, such as announcements by competitors and service providers.
The contents of this press release are presented as a general overview of the company. It is intended only to contain general information regarding the company and its business and does not purport to provide complete disclosure or analysis of all matters, which may be relevant to a decision to make an investment, including all risk factors or similar considerations. Although the information is believed current as of the date herein, the information may be subject to change, amendment or supplementation, and the company does not expect, and assumes no obligation, to update or otherwise revise the information herein.
CONTACT: Curaxis Pharmaceutical Corporation David J. Corcoran dcorcoran@curaxispharma.com